welcome to STERNA BIOLOGICALS

Konstantin joined sterna as CEO in June 2023. Prior to this, he was CEO of AMW GmbH, a revenue-generating specialty pharmaceuticals company. In addition to his role at sterna, he also serves as CBO of Secarna Pharmaceuticals.

Over the last 10 years, Konstantin has held senior management positions at several biotech and pharma companies. In addition to AMW, he held key positions at Leukocare AG, Bayer AG and MorphoSys AG. During his time at AMW, he re-shaped the strategy for the company to enhance its commercial viability and to focus on AMW’s core value drivers, including operational scale-up, replenishing the pipeline, as well as refocusing on AMW’s key technology, biodegradable implants. At Leukocare, he headed all business development, sales and marketing activities, achieving year-over-year growth of approximately 50%. At MorphoSys, he held positions of increasing responsibility, and in his role as head of the pre-commercial group, he was the point person to build and grow MorphoSys's newly to be established commercial department.

Konstantin has a PhD in oncology from the Ludwig-Maximilians-University, Munich, Germany and holds an MBA from the University of Applied Sciences for Economics and Management.

Daniel has worked in pharmaceutical R&D with a focus on inflammatory diseases for more than 20 years. His expertise spans from early drug discovery to clinical proof of concept and beyond. He held R&D positions at Novartis and Revotar Biopharmaceuticals before working as an independent expert, advisor and consultant.

Daniel received a Ph.D. from the University of Hannover, Germany.

Marion joined sterna biologicals in early 2019 as its Chief Medical Officer. Prior to this, she worked in leading positions at Talecris (now Grifols), and GSK, where she was Therapeutic Area Director Respiratory. Previously, Marion worked as Medical Director for a phase I research clinic at CRS Clinical Research Services Mannheim and held a number of positions in academic teaching hospitals and CROs with a strong focus on inflammatory/respiratory diseases and plasma products.

Marion holds a MD from the University of Freiburg, Germany, and is a board-certified internist and pneumonologist.

Nina joined sterna in January 2021 and has contributed significantly to the development of the Company’s programs. In September 2023, she was promoted to Chief Operating Officer./p>

Nina has more than twelve years of experience in the pharmaceutical industry, where she developed strong management skills. Prior to her time at sterna, Nina held several leading roles in R&D, program management and product development at Vectura GmbH and medac GmbH.

From 2007 to 2011, she worked at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, where she also acquired a PhD in Biology.

Thomas joined sterna biologicals in 2019 coming from INJEX Pharma, a medical device company specializing in needle-free injection systems. Prior to this, he worked as Chief Financial Officer and deputy Chief Executive Officer in several publicly listed companies including Marseille-Kliniken and Medigene, where he supported/led their first SEDA financing in Germany and the company’s listing on TecDAX, Germany´s Top 30 Technology Companies index.

Thomas was also an Assistant Professor at the University of Mannheim in Germany and a Research Fellow at the M.I.T. Sloan School of Management in Boston, where his research focused on innovation management and organizational changes in industrial corporations. Thomas holds a Ph.D. in Business Economics from the University of Mannheim, Germany, a Master’s in Engineering from the University of Karlsruhe, Germany and is a Harvard Business School - Executive Education Program graduate.